 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
8 News |  |
- || Myalept (metreleptin) / Novelion, pramlintide/metreleptin (AC137-164594) / BMS, Mounjaro (tirzepatide) / Eli Lilly
Yes ofc but now we need CURE CURE CURE. MC4R, tirzepatide, pramlintide/metreleptin. Unless genetic polymorphisms or extreme childhood obesity, we need to step in for the older obese populations (Twitter) - Sep 8, 2022
- | Myalept (metreleptin) / Novelion, pramlintide/metreleptin (AC137-164594) / BMS
I had a minor obsession with the metreleptin pramlintide combo..... https://t.co/PmRrCRGR36 but it dropped off the radar for some reason (Twitter) - Jul 29, 2022
- || Myalept (metreleptin) / Novelion, pramlintide/metreleptin (AC137-164594) / BMS
prescribing metreleptin with pramlintide tho https://t.co/PmRrCRGR36 (Twitter) - Feb 9, 2022
- |||| Myalept (metreleptin) / Novelion, pramlintide/metreleptin (AC137-164594) / BMS
Clinical: It also worked in some of the kids in Lustig's studies on hypothalamic obesity. I don't recall if this was reported but may have happened in the metreleptin/pramlintide studies on adults with obesity (Twitter) - Apr 8, 2021
- ||| Myalept (metreleptin) / Novelion, pramlintide/metreleptin (AC137-164594) / BMS
Interesting. Liebel's studies were replacing leptin to pre-weight loss levels. Metreleptin doesn't do much in obesity (besides genetic polymorphs). I liked the pramlintide/metreleptin story, but apparently big pharma didn't https://t.co/L1GxK4VvGc or here https://t.co/PmRrCRGR36 (Twitter) - Apr 8, 2021
- | Myalept (metreleptin) / Novelion, pramlintide/metreleptin (AC137-164594) / BMS
Trial termination: A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects (clinicaltrials.gov) - Nov 13, 2013
P2, N=213, Terminated, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Terminated; Results from previous study DFA102 demonstrated neutralizing activity to metreleptin in invitro assay in 2 participants.
- ||| Myalept (metreleptin) / Novelion
Enrollment change, Combination therapy: Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin (clinicaltrials.gov) - Nov 12, 2013
P2, N=274, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Terminated; Results from previous study DFA102 demonstrated neutralizing activity to metreleptin in invitro assay in 2 participants. N=400 --> 274
- |||| Myalept (metreleptin) / Novelion
Trial completion, Combination therapy: Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin (clinicaltrials.gov) - Nov 12, 2013
P2, N=274, Completed, Sponsor: Bristol-Myers Squibb
N=400 --> 274 Active, not recruiting --> Completed